Skip Ribbon Commands
Skip to main content
Clin Asst Prof Jolene Wong Si Min

Clin Asst Prof Wong Jolene

MBBS, MMED, FRCS Ed (Gen Surg)


Specialty: Surgery & Surgical Oncology

Clinical Interest: Peritoneal-based Malignancies, Sarcoma, Skin & Melanoma, Upper Gastrointestinal, Surgery & Surgical Oncology

Conditions Treated by this Doctor:
Colorectal Cancer, Ovarian Cancer, Peritoneal based Malignancies, Sarcoma, Sarcoma and Melanoma, Skin Cancer, Stomach Cancer, Upper Gastrointestinal Cancers.

Clinical Appointments

  • Visiting Consultant Gynaecological Oncology KK Women's and Children's HospitalKK Women's and Children's Hospital
  • Consultant Division of Surgery & Surgical Oncology National Cancer Centre SingaporeNational Cancer Centre Singapore
  • Consultant Sarcoma, Peritoneal and Rare Tumours (SPRinT) Singapore General HospitalSingapore General Hospital

Academic Appointments

  • Clinical Lecturer, NUS YLLSOM
  • Teaching Faculty: Clinical Teacher, Content Expert, Clinical Practice Facilitator, LKC NTU Medical School
  • Physician Faculty, SingHealth PGY1 Residency
  • Physician Faculty, SingHealth General Surgery Residency
  • Clinical Assistant Professor, SingHealth Duke NUS Surgery Academic Clinical Programme & Oncology Academic Clinical Programme


Dr Jolene Wong is a Consultant at the Department of Sarcoma, Peritoneal and Rare Tumors (SPRinT). She graduated from the National University of Singapore (NUS) Yong Loo Lin School of Medicine Singapore with consecutive Dean’s list awards in 2014 and subsequently completed her General Surgery specialist training at Singhealth in 2019. She is a fellow of the Royal College of Surgeons (Edinburgh) and holds a Master of Medicine (Surgery). Having completed 2 years of local subspecialty training in the treatment of sarcoma, peritoneal surface malignancy, and skin cancers at the Singapore General Hospital (SGH) and KK Women’s & Children Hospital; Dr Wong continued to pursue her interest in innovative and minimally invasive approaches in the treatment of peritoneal disease at Ghent University Hospital, Belgium where she focused on the conduct of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) and Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC).

As a health services researcher with an interest in population health, Dr Wong holds a Master of Public Health (MPH) from the Harvard TH Chan School and completed her research fellowship at the Centre of Surgery and Public Health, Brigham and Women Hospital, Boston in 2023. Leveraging on her training in patient reported outcomes, health economics, data science and health services delivery, Dr Wong hopes to improve the quality of care for seriously ill older adults in surgery. Since 2019, she has received 6 institutional and national grants, including the Duke-NUS Nurturing Clinician Scientist Award in 2021 and the National Medical Research Council (NMRC) Population Health New Investigator Award in 2023. She has co-authored more than 40 peer reviewed publications over the last 5 years. In the arena of innovative technologies, Dr Wong led and completed Singhealth’s 1st PIPAC trial which has the potential to effectively palliate symptoms and improve survival in patients with peritoneal disease.

A pioneer in palliative surgical care research in Singapore and in the region, Dr Wong established the country’s first palliative surgery and intervention workgroup in 2020, providing a multi-disciplinary platform to improve care in this vulnerable group. She is also represents Singhealth in the Ministry of Health End of Life (EOL) value driven care initiative. Recognising the importance of increasing awareness in serious illness and palliative surgical education, Dr Wong spearheaded the palliative education program for Singhealth’s surgeons and hopes to further such initiatives in the future. She also has strong collaborations with population health teams with ongoing initiatives aimed at the delivery of specialist surgical oncology care in the community for older adults with serious illness.

Dr Wong is also active and passionate about medical education and training and is a clinician faculty member of the Sing health General Surgery Residency Program me and a clinical tutor to students from NUS, Duke and NTU.


  • Master of Public Health (MPH), Harvard T.H Chan School of Public Health, USA, May 2023
  • Fellowship of the Royal College of Surgeons (FRCS), Royal College of Surgeons of Edinburgh, Aug 2019
  • Intercollegiate Membership of the Royal College of Surgeons (MRCS), Royal College of Surgeons of Edinburgh, Oct 2018
  • Master of Medicine (Surgery), Royal College of Surgeons of Edinburgh, Jul 2016
  • Bachelor of Medicine & Surgery (MBBS), Yong Loo Lin School of Medicine, NUS, May 2014

Professional Appointments and Committee Memberships

  • Clinician Champion, Cytoreductive Surgery Value-driven Care Workgroup, Singapore General Hospital/ Singapore
  • Clinician Champion, Serious Illness Value-driven Care Workgroup, Singapore General Hospital/ Singapore
  • Clinician Champion, SPRinT Surgeries Value-driven Care Workgroup, Singapore General Hospital/ Singapore
  • Lead, SingHealth Peritoneal Surface Malignancy Registry Development, SingHealth/ Singapore
  • Chairperson, SingHealth Multi-Disciplinary Palliative Intervention Workgroup, National Cancer Centre Singapore/ Singapore
  • Committee Member, Medisave Audit Committee, Singapore General Hospital/ Singapore
  • Executive Committee, Cancer Education and Information Services, National Cancer Centre Singapore/Singapore 
  • Executive Committee, Resource Allocation & optimization, National Cancer Centre Singapore/Singapore
  • Committee Member, Asian Peritoneal Surface Malignancy Group, Singapore


Research Interests

  • Surgical Oncology
  • Peritoneal Surface Malignancy
  • Sarcoma
  • Health Services Research
  • Patient Reported Outcomes 
  • Palliative Surgical Care


  • Knowledge and thresholds for palliative care and surgery among healthcare providers caring for adults with serious illness. Juan WKD, Ng IAT, Wong LCK, Fong WJ, Lee PP, Lie SA, Zhou JX, Cai M, Ong JC, Seo JCJ, Chia CS, Wong JSM. Front Med. 2024 May 31;11:1351864. [JIF: 3.82]
  • ASO Author Reflections: Enhancing Palliative Care Delivery: The Potential of Multi-Disciplinary Intervention Teams for Surgical Oncology Patients. Juan WKD, Soon JJY, Wong JSM. Ann Surg Oncol. 2023 Sept 7. [JIF:5.344]
  • Implementation of a Multi-Disciplinary Team and Quality of Goals of Care Discussions in Palliative Surgical Oncology Patients. Soon JJY, Juan WKD, Ong WS, Bek S, Neo PSH, Salazar E, Zhuang KD, Tan YP, Chia CS, Wong JSM. Ann Surg Oncol. 2023 Sept 7. [JIF:5.344]
  • Novel use of natural language precession for registry development in peritoneal surface malignancies. Shannon NB, Wong LCK, Nakayama M, Tran NTA, Cheng LTE, Thing CH, Abdullah HRB, Juan WKD, Lum MJD, Ong CAJ, Seo CJ, Chia CS, Wong JSM. Info Med Unlocked. 2023 Jul 14; 101309. [JIF: 6.26] 
  • Trajectories of Patient-Reported Outcomes after Palliative Gastrointestinal Surgery in Advanced Cancer: Is Good Quality of Life Sustainable? Wong JSM, Ng IAT, Juan WKD, Ong WS, Yang GM, Finkelstein EA, Gandhi M, Ong CAJ, Seo CJ, Zhu HY, Chia CS. Annals of Surgery Open. 2022 Dec;3(4):p e206. [JIF: 13.787]
  • Palliative Gastro-intestinal Surgery in Patients with Advanced Peritoneal Carcinomatosis: Clinical Experience and Development of a Predictive Model for Surgical Outcomes. Wong JSM, Lek SM, Lim YZD, Chia CS, Tan GHC, Ong C-AJ, Teo MCC. Front Oncol. 2022 Jan 13; 11:811743. [JIF: 6.244]
  • A Systematic Review on Quality of Life (QoL) of Patients with Peritoneal Metastasis (PM) who Underwent Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC). Li Z, Wong LCK, Sultana R, Wong JSM, et al. Pleura and Peritoneum. 2022 Apr 21;7(2):39-49. [JIF: 1.64]
  • Attitudes, Knowledge & Awareness Amongst Physicians in the Management Of Peritoneal-Surface Based Malignancies. Wong JSM, Ng IAT, Paik B, Ong CJ, Seo CJ, Lee PP, Zhu HY, Chia CS. Asian Journal of Surgery. 2022 Jun 24;45(12):2829-2831[JIF: 1.49]
  • Can Baseline Quality of Life Scores Predict for Morbidity and Survival after CRS and HIPEC: A Prospective Study of 151 Patients. Chia CS, Ong CAJ, Zhu HY, Wong JSM, et al. Pleura and Peritoneum. 2022 Apr 4;7(2):63-75. doi:10.1515/pp-2021-0148 [JIF: 1.64]
  • Department of Sarcoma, Peritoneal and Rare Tumors (SPRinT): A subspecialty surgical oncological care model for advanced malignancies requiring complex procedures. Tu IW*, Wong JSM*, Tan QX, Ng G, Ong CJ, Chia CS. Asian J Surg. 2022 Jan;45(1):546-548. [JIF: 2.767] (*co-first authors)
  • Facilitating Timely Cancer Care in a Surgical Oncology Subspecialty Unit During the Pandemic And Recovery Phase of the COVID era. Ong CJ, Lim HJ, Tan JW, Wong JSM, Chia C. Asian J Surg. 2020 Jul 23; 43(9):965-966. [JIF: 2.767]
  • Incidence and Outcomes of Delayed Presentation and Surgery in Peritoneal Surface Malignancies. Tan JKT, Wong JSM*, Seo CJ, Lim C, Zhu HY, Ong CAJ, Chia CS. Front Oncol. 2023 May 30;13;1137785. [JIF: 5.738] (*co-first authors)
  • Electromotive Enhanced Drug Administration in Oncology: Principles, Evidence, Current and Emerging Applications. Wong JSM, Saeed N, Coene A, Adriaens M, Ceelen W. Cancers 2022. 2022 Oct 11;14(20):4980. [JIF: 6.575]
  • Randomized Controlled Trial Investigating Perioperative Immunonutrition for Patients Undergoing Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC). Tan GHC, Chia CS, Wong JSM, Ong WS, Zhu HY, Ong CJ, Teo MCC. Ann Surg Oncol. 2022 Sep 30;30(2):777-789. [JIF:5.344]
  • An Asian Tertiary Centre’s Early Experience with Laparoscopic Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis. Linn YL, Seo CJ, Wong JSM, Ong CSJ, Chia CS. Indian Journal of Surgical Oncology. 2022 Sep 9;14:175-180. [JIF: 0.54]
  • High Intra-Abdominal Pressure During Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Following Cytoreductive Surgery (CRS) for Peritoneal Surface Malignancies. Wong LCK*, Wong JSM*, Seo CJ, Soo KC, Ong CJ, Chia CS. Int J Hyperthermia. 2022 Sep 2;39(1):1195-1201. (*Co-first authors) [JIF 3.98]
  • A Systemic Review of Margin Status in Retroperitoneal Liposarcomas: Does the Ro Margin Matter? Paik B, Seo CJ, Tan JWS, Juan WKD, Soo KC, Ong CAJ, Chia CS, Wong JSM. Front Oncol. 2022 Aug 11;12:891710. [JIF: 5.738]
  • Prospective Comparison of the Performance of MRI Versus CT in the Detection and Evaluation of Peritoneal Surface Malignancies. Chia CS, Wong LCK, Hennedige TP, Ong WS, Zhu HY, Tan GHC, Kwek JW, Seo CJ, Wong JSM, Ong CJ, Thng CH, Soo KC, Teo MCC. Cancers (Basel). 2022 Jun 29;14(13):3179. [JIF: 6.575]
  • Implications of peritoneal cancer index distribution on patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Wong JSM, Tan GHC, Cheok SHX, et al. Pleura Peritoneum. 2022 Apr 26;7(2):95-102. [JIF: 1.64]
  • Cytoreductive Surgery (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Peritoneal Sarcomatosis – A Systematic Review and Meta-Analysis. Wong LCK*, Li Z*, Qiao F, Tan JWS, Tan QX, Wong JSM, Ong C-AJ, Chia CS. Eur J Surg Oncol. 2022 Mar; 48(3):640-648 [JIF: 4.424]
  • Ligand-mediated PAI-1 Inhibition in a Mouse Model of Peritoneal Carcinomatosis. Hendrikson J*, Liu Y*, Ng WH, Lee JY, Lim AH, Loh JW, Ng CCY, Ong WS, Tan JWS, Tan QX, Ng G, Shannon NB, Lim WK, Lim TKH, Chua C, Wong JSM, Tan GHC, So JBY, Yeoh KG, Teh BT, Chia CS, Soo KC, Kon OL, Tan IBH, Chan JY, Teo MCC, Ong CAJ, Singapore Peritoneal Oncology Study (SPOS) Group and Singapore Gastric Cancer Consortium (SGCC) (2022) Cell Rep Med. 2022 Feb 15;3(2): 100526 [JIF: 14.3]
  • Effect of HIPEC on Peritoneal Recurrence in Peritoneal Metastasis Treated with Cytoreductive Surgery: A Systematic Review. Yap DRY*, Wong JSM*, Tan QX, Tan JWS, Chia CS, Ong C-AJ. Front Oncol. 2021 Dec 3; 11:795390 (*co-first author) [JIF: 6.244] 
  • The Role of Total Parenteral Nutrition in Patients with Peritoneal Carcinomatosis: A Systematic Review and Meta-Analysis. Ong XYS, Sultana R, Tan JWS, Tan QX, Wong JSM, Chia CS, Ong CAJ. Cancers (Basel). 2021 Aug 18; 13(16): 1456 [JIF: 6.639]
  • A Machine Learning Approach to Identify Predictive Molecular Markers for Cisplatin Chemosensitivity Following Surgical Resection in Ovarian Cancer. Shannon NB*, Tan LLY*, Tan QX, Tan JWS, Hendrikson J, Ng WH, Ng G, Liu Y, Ong XYS, Nadarajah R, Wong JSM, Tan GHC, Soo KC, Teo MCC, Chia CS, Ong C-AJ. Sci Rep. 2021 Aug 19; 11: 16829 (* Equal contribution) [JIF: 4.379]
  • Predicting Early and Late Readmissions Following Cytoreductive Surgery & Hyperthermic Intraperitoneal Chemotherapy. Moon EW, Wong JSM, See AHM, Ong WS, Tan CA, Ong CAJ, Chia CS, Soo KC, Teo MCC, Tan GHC. Ann Surg Oncol. 2021 Jul 24; 28(11):6613-6624 [JIF: 5.344]
  • Gene Expression Changes Associated with Dedifferentiation in Liposarcoma Predict Overall Survival. Shannon NB, Tan QX, Tan JWS, Hendrikson J, Ng WH, Ng G, Liu Y, Tan GHC, Wong JSM, Soo KC, Teo MCC, Chia CS, Ong C-AJ. Cancers (Basel). 2021 Jun 18; 13(12): 3049 [JIF: 6.639]
  • ASO Author Reflections: Postoperative Inflammatory Markers as a Surveillance Tool in Colorectal Peritoneal Carcinomatosis. Tan JWS, Thiagarajan S, Zhou S, Tan QX, Hendrikson J, Ng WH, Ng G, Liu Y, Wong JSM, Tan GHC, Soo KC, Teo MCC, Chia CS, Ong C-AJ. Ann Surg Oncol. 2021 Mar 17;28: 6636-6637. [JIF: 5.344]
  • Neoadjuvant Tyrosine Kinase Inhibitors in Rectal Gastrointestinal Stromal Tumours: A Provision for Enhanced Oncological and Functional Outcomes. Yong ZZ, Wong JSM, Teo MCC, Chia CS, Ong CJ, Farid M, Tan GHC. Int J Clin Oncol. 2021 Feb 2. [JIF 2.879]
  • Surgical Management and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Locally Advanced Colorectal Cancer. Tan G, Wong J. J Gastrointest Oncol. 2020 Jun;11(3):508-512. [JIF: 2.892]
  • Management of Synchronous Lateral Pelvic Nodal Metastasis in Rectal Cancer in the era of Neoadjuvant Chemoradiation: A systemic review. Wong JSM, Tan GHC, Chia CS, Ong CJ, Teo MCC. World J Gastrointest Surg. 2020 May 27;12(5):247-258. [JIF: 2.582]
  • The Importance of Synchronicity in the Management of Colorectal Peritoneal Metastases with Cytoreductive Surgery & Hyperthermic Intraperitoneal Chemotherapy. Wong J, Tan G, Chia C, Ong J, Ng WY, Teo M. World J Surg Oncol. 2020 Jan 13;18(1):10 [JIF: 2.754]
  • The Impact of Emergency Readmissions Following Cytoreductive Surgery & Hyperthemic Intraperitoneal Chemotherapy. Wong J, Tan G, See A, Chia C, Ong J, Soo K, Teo M. Ann Surg Oncol. 2020 Feb 1; 27(SUPPL 1):S159-S160. [JIF: 5.344]
  • The Development of Robotic Hepatopancreatobiliary Surgery in Singapore: A Multi-Institutional Experience. Lee LS, Wong J, Kah AHC, Lee SY, Chan CY, Tan SS, Teo JY, Goh BK. Ann Laparosc Endosc Surg. 2018 Jul 6; 3(7). [JIF: 0.5]
  • Is Multivisceral Resection in Locally Advanced Gastrointestinal Stromal Tumours an Acceptable Strategy? Wong JSM, Tan GHC, Quek R, Goh BKP, Kwok LL, Kumar M, Soo KC, Teo MCC. ANZ J Surg. 2017 Jun 9; 87(6):477-482. [JIF: 1.872]
  • Management of Para-Aortic Lymph Node Metastasis in Colorectal Patients: A systemic review. Wong JS, Tan GH, Teo MC. Surg Oncol; 2016 Dec; 25(4):411-418. [JIF: 3.279]
  • Role of Upfront Surgery for Recurrent Gastrointestinal Stromal Tumours. Tan GH, Wong JS, Quek R, Goh BK, Kwok LL, Pan S, Soo KC, Teo MC. ANZ J Surg; 2016 Nov 09; 86(11):910-915. [JIF: 1.872]
  • False Negative Rate for Intraoperative Sentinel Lymph Node Frozen Section in Patients with Breast Cancer: A Retrospective Analysis of Patients in a Single Asian Institution. Wong J, Yong WS, Thike AA, Iqbal J, Salahuddin AS, Ho GH, Madhukumar P, Tan BK, Ong KW, Tan PH. J Clin Pathol; 2015 Jul 1; 68(7):536-40. [JIF: 3.411]
  • Hypertension Management and Lifestyle Changes Following Screening for Hypertension in an Asian Low Socioeconomic Status Community: A Prospective Study. Wee LE, Wong J, Chin RT, Lin ZY, Goh DE, Vijakumar K, Vong KY, Tay WL, Lim HT, Koh GC. Ann Acad Med Singap. 2013;42(9):451-465. [JIF: 2.473]
  • Screening for Cardiovascular Disease Risk Factors in an Urban Low-Income Setting at Baseline and Post Intervention: A Prospective Intervention Study. Wee LE, Koh GC, Yeo WX, Chin RT, Wong J, Seow B. Eur J Prev Cardiol; 2013 Feb 1; 20(1):176-88. [JIF: 7.804]

Research Trials

  • Implementation of a Generalist-Specialist Palliative Oncology Care Model amongst Advanced Cancer Surgical Patients: A Pilot Cluster Randomized Control Trial (Ongoing, Study Role: PI)
  • Palliative Care Delivery in Advanced Cancer Surgical Patients: Pilot testing and Implementation of a Novel Natural Language Processing Artificial Intelligence Solution (Ongoing, Study Role: PI)
  • Pilot Testing and Implementation of a General Palliative Education Programme to Optimize Surgical Education & Training in End-of-Life Care (Ongoing, Study Role: PI)
  • Prospective Clinical Trial Evaluating the Efficacy of Pressurised Intra-Peritoneal Chemotherapy (PIPAC) in Palliation of Patients with Unresectable Peritoneal Metastases (Ongoing, Study Role: PI)
  • Measuring Quality of Care among Patients with Cancer during their End-of-Life (Ongoing, Study Role: Co-I)
  • Exosomal biomarker predictor of post-surgical peritoneal recurrence to infer treatment strategies (Ongoing, Study Role: Co-I)
  • Investigating the utility of novel PAI-1 biologics in peritoneal carcinomatosis (Ongoing, Study Role: Co-I)